ST East Ocean denied the rubbing of scenic spots, the new coronary pneumonia kit is expected to be available within the year

ST East Ocean denied the rubbing of scenic spots, the new coronary pneumonia kit is expected to be available within the year
On the evening of March 17, Shandong Dongfang Ocean Technology Co., Ltd. (“ST East Ocean” for short) responded to the Shenzhen Stock Exchange’s concern letter that the company did not actively cater to market hotspots and affected possible situations regarding the progress of the new coronary pneumonia kit.At the same time, ST East Ocean has established cooperation intentions with three clinical trial units to carry out clinical trials of kits. After obtaining national qualifications, it will be launched within the year.On March 13, ST East Ocean received a letter of concern from the Shenzhen Stock Exchange because it discovered the development progress of the new coronary pneumonia kit on the investor interactive platform “Interaction.”On March 17, ST East Ocean responded that the new coronavirus antibody detection kit (enzyme-linked immunoassay) and the new coronavirus antibody detection kit (colloidal gold method) were provided by the subsidiary Oriental Ocean (Beijing) Medical Research Institute, AviThe research and development team of Ke Biological Technology Co., Ltd. develops separately, the former can be in 1.The high-throughput test of 96 samples was completed within 5 hours, and the test results can be interpreted in the remaining 15 minutes, but the above test kit is not a patented product.At present, ST East Ocean has completed relevant R & D and trial production, and has determined cooperation intentions with three clinical trial units to carry out clinical trials.After the trial, ST East Ocean will submit product registration information to the State Food and Drug Administration, and after obtaining the medical device product registration certificate, it is expected to be marketed within the year.The data shows that ST East Ocean is mainly engaged in the ecological farming of marine pastures, the export and deep processing of aquatic products, etc. In 2016, it entered the in vitro diagnostic industry across the border.According to ST East Ocean’s response, the research and development entities Oriental Ocean (Beijing) Medical Research Institute and Avic Biotechnology Co., Ltd. each received net profit of 18 in 2019.1% and 12.03% of R & D investment, but net profit was invested 213 respectively.80 thousand yuan and 601.230,000 yuan, accounting for 0 in the consolidated statement.39% and 1.09%.ST East Ocean believes that Jungle ‘s answer to the R & D progress of reagents on the “Easy Interactive” platform belongs to the daily R & D development of the Health Department, and is not an important matter ST ST Ocean should disclose.And since the reply, it has always been stable, there is no abnormality, there is no fact that it actively caters to market hotspots, affects outstanding, and there is no fact that violates the fair exposure of information.Sauna, Ye Wang Editor Wang Siyang Zhu Fenglan proofreading Wang Xin

Comments

No comments yet.
Comments are closed